MCA
AMRX icon

McGuire Capital Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

McGuire Capital Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.5K Sell
4,422
-2,198
-33% -$30.1K 0.04% 159
2026
Q1 		$82.3K Hold
6,620
– – 0.05% 147
2025
Q4 		$83.4K Buy
+6,620
New +$75.7K 0.05% 150

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

McGuire Capital Advisors's AMRX Position: Q2 2026 in Review

McGuire Capital Advisors reduced its Amneal Pharmaceuticals (AMRX) stake by 33% in Q2 2026, selling an estimated $30.1K and leaving 4,422 shares worth $76.5K. The position accounts for 0.04% of the portfolio, ranked #159.

McGuire Capital Advisors first reported a position in AMRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $83.4K in Q4 2025. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • McGuire Capital Advisors held 4,422 shares of Amneal Pharmaceuticals worth $76.5K as of Q2 2026.
  • McGuire Capital Advisors sold 2,198 Amneal Pharmaceuticals shares in Q2 2026, an estimated $30.1K.
  • Amneal Pharmaceuticals made up 0.04% of McGuire Capital Advisors's portfolio in Q2 2026, its #159 holding.
  • McGuire Capital Advisors first reported a position in Amneal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • McGuire Capital Advisors's Amneal Pharmaceuticals position peaked at $83.4K in Q4 2025.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on McGuire Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.